These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6790269)

  • 1. Urinary excretion of LATS in a patient with Graves' disease complicated by nephrotic syndrome.
    Kajita Y; Miyoshi Y; Hachiya T; Miyazaki T; Yoshimura M; Ijiichi H; Ochi Y
    Endocrinol Jpn; 1980 Dec; 27(6):727-32. PubMed ID: 6790269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum long acting thyroid stimulator (LATS) and LATS-protector (LATS-P) in Graves' disease associated with localized myxedema.
    Hardisty CA; Fowles A; Munro DS
    J Endocrinol Invest; 1984 Apr; 7(2):151-5. PubMed ID: 6547156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissociation of serum LATS activity and hyperfunction and autonomy of the thyroid gland in Graves' disease.
    Hennemann G; Dolman A; Docter R; De Reus A; Van Zijl J
    J Clin Endocrinol Metab; 1975 Jun; 40(6):935-41. PubMed ID: 1173367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prediction of relapse after drug treatment of Graves' disease by assay of long acting thyroid stimulator-protector (LATS-P).
    Hardisty CA; Hanford L; Munro DS
    Clin Endocrinol (Oxf); 1981 May; 14(5):509-17. PubMed ID: 6895487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graves' disease with delayed hyperthyroidism. Onset after several years of euthyroid ophthalmopathy, dermopathy, and high serum LATS.
    Chopra IJ; Solomon DH
    Ann Intern Med; 1970 Dec; 73(6):985-90. PubMed ID: 5538174
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of partial thyroidectomy for Graves' disease on serum long-acting thyroid stimulator protector (LATS-P).
    Hardisty CA; Talbot CH; Munro DS
    Clin Endocrinol (Oxf); 1981 Feb; 14(2):181-8. PubMed ID: 6894891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human thyroid adenyl cyclase-stimulating activity in immunoglobulin G of patients with Graves' disease.
    Orgiazzi J; Williams DE; Chopra IJ; Solomon DH
    J Clin Endocrinol Metab; 1976 Feb; 42(2):341-54. PubMed ID: 946604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of LATS activity and TSH receptor antibody in Graves' disease.
    Kajita Y; Nakajima Y; Ishida M; Ura Y; Ochi Y; Miyazaki T; Hachiya T; Ijichi H
    Endocrinol Jpn; 1984 Jun; 31(3):369-74. PubMed ID: 6094169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting thyroid stimulator (LATS) and long acting thyroid stimulator protector (LATS-P) in untreated thyrotoxicosis.
    Hardisty CA; Hanford L; Humphries H; Munro DS
    Clin Endocrinol (Oxf); 1981 Jun; 14(6):631-9. PubMed ID: 6895353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between long-acting thyroid stimulator protector level and thyroid 131-I uptake in thyrotoxicosis.
    Adams DD; Kennedy TH; Stewart RD
    Br Med J; 1974 Apr; 2(5912):199-201. PubMed ID: 4406686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does LATS cause hyperthyroidism in Graves' disease? (A review biased toward the affirmative).
    McKenzie JM
    Metabolism; 1972 Sep; 21(9):883-94. PubMed ID: 4115791
    [No Abstract]   [Full Text] [Related]  

  • 12. Concentration of long-acting thyroid stimulator (LATS) by subfractionation of gamma G globulin from Graves' disease serum.
    Miyai K; Werner SC
    J Clin Endocrinol Metab; 1966 May; 26(5):504-12. PubMed ID: 5952570
    [No Abstract]   [Full Text] [Related]  

  • 13. [Studies on the purification and the immunological properties of LATS-immunoglobulin (author's transl].
    Miyazaki T
    Nihon Naibunpi Gakkai Zasshi; 1978 Jul; 54(7):815-28. PubMed ID: 710642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoelectric focusing of long-acting thyroid stimulator (LATS) containing IgG.
    Schleusener H; Adlkofer F; Uher L; Kaper-Czygan S; Kirstaedter HJ
    Horm Metab Res; 1971 May; 3(3):221-2. PubMed ID: 5171402
    [No Abstract]   [Full Text] [Related]  

  • 15. Placental transmission of thyroid-stimulating immunoglobulins.
    Dirmikis SM; Munro DS
    Br Med J; 1975 Jun; 2(5972):665-6. PubMed ID: 1173561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between thyroid stimulating and tsh-binding inhibiting immunoglobulins of Graves' disease.
    Macchia E; Fenzi GF; Monzani F; Lippi F; Vitti P; Grasso L; Bartalena L; Baschieri L; Pinchera A
    Clin Endocrinol (Oxf); 1981 Aug; 15(2):175-82. PubMed ID: 6118213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transient thyrotoxicosis in an infant delivered to a long-acting thyroid stimulator (LATS)- and LATS protector-negative, thyroid-stimulating antibody-positive woman with Hashimoto's thyroiditis.
    Hoffman WH; Sahasrananan P; Ferandos SS; Burek CL; Rose NR
    J Clin Endocrinol Metab; 1982 Feb; 54(2):354-6. PubMed ID: 6119322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of radioablation of the thyroid gland in Graves' disease with high levels of long-acting thyroid stimulator (LATS).
    Volpé R; Desbarats-Schonbaum ML; Schonbaum E; Row VV; Ezrin C
    Am J Med; 1969 Feb; 46(2):217-26. PubMed ID: 5818477
    [No Abstract]   [Full Text] [Related]  

  • 19. Detection and properties of TSH-binding inhibitor immunoglobulins in patients with Graves' disease and Hashimoto's thyroiditis.
    Endo K; Kasagi K; Konishi J; Ikekubo K; Okuno T; Takeda Y; Mori T; Torizuka K
    J Clin Endocrinol Metab; 1978 May; 46(5):734-9. PubMed ID: 45421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of long-acting thyroid stimulator (LATS) and LATS protector on human thyroid adenyl cyclase activity.
    Kendall-Taylor P
    Br Med J; 1973 Jul; 3(5871):72-5. PubMed ID: 4740444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.